Mydecine Innovations Group Beheer

Beheer criteriumcontroles 3/4

De CEO Mydecine Innovations Group is Josh Bartch, benoemd in Jul2018, heeft een ambtstermijn van 6.33 jaar. bezit rechtstreeks 0.61% van de aandelen van het bedrijf, ter waarde € 1.92K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 4.4 jaar.

Belangrijke informatie

Josh Bartch

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6.3yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Josh Bartch's beloning veranderd ten opzichte van Mydecine Innovations Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CA$12m
Jun 30 2024	n/a	n/a	-CA$12m
Mar 31 2024	n/a	n/a	-CA$11m
Dec 31 2023	n/a	n/a	-CA$21m
Sep 30 2023	n/a	n/a	-CA$19m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$21m
Dec 31 2022	CA$445k	CA$383k	-CA$16m
Sep 30 2022	n/a	n/a	-CA$23m
Jun 30 2022	n/a	n/a	-CA$18m
Mar 31 2022	n/a	n/a	-CA$24m
Dec 31 2021	CA$2m	CA$346k	-CA$24m
Sep 30 2021	n/a	n/a	-CA$19m
Jun 30 2021	n/a	n/a	-CA$37m
Mar 31 2021	n/a	n/a	-CA$32m
Dec 31 2020	CA$819k	CA$153k	-CA$27m
Sep 30 2020	n/a	n/a	-CA$39m
Jun 30 2020	n/a	n/a	-CA$23m
Mar 31 2020	n/a	n/a	-CA$20m
Dec 31 2019	CA$238k	CA$238k	-CA$21m
Sep 30 2019	n/a	n/a	-CA$5m
Jun 30 2019	n/a	n/a	-CA$5m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$425k	CA$302k	-CA$13m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Josh redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de German markt.

Compensatie versus inkomsten: De vergoeding van Josh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Josh Bartch (36 yo)

6.3yrs

Tenure

CA$444,518

Compensatie

Mr. David Joshua Bartch, also known as Josh, serves as Chairman of the Board at Mydecine Innovations Group Inc. Mr. Bartch is Co-Founder of Mydecine Innovations Group Inc. and serves as its President, Chie...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Bartch	Co-Founder	6.3yrs	CA$444.52k	0.61% € 1.9k
Robert Roscow	Co-Founder	4.5yrs	CA$455.31k	0.21% € 649.8
Damon Michaels	Co-Founder & COO	4.5yrs	CA$455.31k	0.15% € 463.8
John Ross	CFO & Corporate Secretary	2.2yrs	CA$9.20k	geen gegevens
Sanford Stein	Chief Compliance Officer & General Counsel	4.1yrs	CA$317.36k	geen gegevens
Rakesh Jetly	Chief Medical Officer	4yrs	CA$271.20k	geen gegevens
Morgan Kervitsky	Director of Marketing	no data	geen gegevens	geen gegevens
Michel Rudolphie	President of the European Operations	3.7yrs	geen gegevens	geen gegevens
William Cook	Interim CEO & Technical Director of Mindleap Health Inc.	3.5yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van 0NF0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Bartch	Co-Founder	6.4yrs	CA$444.52k	0.61% € 1.9k
Robert Roscow	Co-Founder	3.9yrs	CA$455.31k	0.21% € 649.8
Anton Gomez-Escolar	Member of Medical	4.4yrs	geen gegevens	geen gegevens
Vince Polito	Member of Medical	4.4yrs	geen gegevens	geen gegevens
Denton Hoyer	Member of Medical	4.4yrs	geen gegevens	geen gegevens
Ruth Lanius	Member of Medical	no data	geen gegevens	geen gegevens
Gary Wynn	Member of Medical	no data	geen gegevens	geen gegevens
Paul Frewen	Member of Medical	no data	geen gegevens	geen gegevens
Rick Barnett	Member of Medical	no data	geen gegevens	geen gegevens
Danielle Wise	Member of Medical	no data	geen gegevens	geen gegevens
David Erritzoe	Member of Medical	4.3yrs	geen gegevens	geen gegevens
Robin Carhart-Harris	Member of Medical	4.3yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 0NF0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Mydecine Innovations Group Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

First half earnings released

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

New 90-day low - €0.24

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

Analyse CEO-vergoeding

CEO

Tenure